{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:42:51Z","timestamp":1792428171842,"version":"4.5.0"},"posted":{"date-parts":[[2026,6,9]]},"group-title":"In Review","reference-count":54,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,5,19]]},"abstract":"<title>Abstract<\/title>\n                <p>Lipid nanoparticles (LNPs) are clinically proven mRNA delivery vehicles, and repeated administration is often required to maintain therapeutic or prophylactic benefit. However, a single dose can provoke adaptive immune responses against polyethylene glycol (PEG), a polymeric excipient on the LNP surface. In this event, resultant anti-PEG antibodies neutralize subsequent LNP doses, causing efficacy loss and limiting therapeutic utility. Here, we investigated whether altering the LNP formulation between initial and subsequent doses could mitigate PEG-associated efficacy loss. Following the administration of an LNP known to elicit anti-PEG antibodies, we re-dosed with LNPs formulated with varied PEG-lipid chemistry, PEG concentration, mRNA cargo, and administration route. None of these adjustments prevented efficacy loss, which consistently correlated with elevated anti-PEG immunoglobulin M (IgM) and, in some cases, immunoglobulin G (IgG). Reduced PEG concentration diminished immunogenicity but also potency, and intraperitoneal dosing elicited the strongest responses upon repeat injection. Further, LNPs that elicit anti-PEG antibodies also impaired the subsequent delivery of an FDA-approved MC3 formulation, suggesting that anti-PEG immune responses can compromise any PEGylated LNP formulation. Together, these findings demonstrate that PEG-associated efficacy loss cannot be resolved through formulation optimization alone. Instead, they suggest that the ionizable lipid\u2019s engagement of innate immune receptors is the primary determinant of repeat dosing success.<\/p>","DOI":"10.21203\/rs.3.rs-9763025\/v1","type":"posted-content","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:28:26Z","timestamp":1780993706000},"source":"Crossref","is-referenced-by-count":0,"title":["PEG-associated efficacy loss in lipid nanoparticles persists across formulation modifications for mRNA delivery"],"prefix":"10.21203","author":[{"given":"Mariah L.","family":"Arral","sequence":"first","affiliation":[{"name":"Carnegie Mellon University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namit","family":"Chaudhary","sequence":"additional","affiliation":[{"name":"Carnegie Mellon University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine C.","family":"Fein","sequence":"additional","affiliation":[{"name":"Carnegie Mellon University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra N.","family":"Newby","sequence":"additional","affiliation":[{"name":"Carnegie Mellon University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saigopalakrishna S.","family":"Yerneni","sequence":"additional","affiliation":[{"name":"Carnegie Mellon University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilian R.","family":"Melamed","sequence":"additional","affiliation":[{"name":"Carnegie Mellon University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel T.","family":"LoPresti","sequence":"additional","affiliation":[{"name":"Carnegie Mellon University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria M. Strelkova","family":"Petersen","sequence":"additional","affiliation":[{"name":"Carnegie Mellon University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A.","family":"Whitehead","sequence":"additional","affiliation":[{"name":"Carnegie Mellon University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMOA2110475\/SUPPL_FILE\/NEJMOA2110475_DISCLOSURES.PDF","article-title":"Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting","volume":"385","author":"Barda N","year":"2021","unstructured":"Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. New Engl J Med Mass Med Soc. 2021;385:1078\u201390. https:\/\/doi.org\/10.1056\/NEJMOA2110475\/SUPPL_FILE\/NEJMOA2110475_DISCLOSURES.PDF.","journal-title":"New Engl J Med Mass Med Soc"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden LR","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New Engl J Med Mass Med Soc. 2021;384:403\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2035389.","journal-title":"New Engl J Med Mass Med Soc"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults","volume":"383","author":"Anderson EJ","year":"2020","unstructured":"Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. New Engl J Med Mass Med Soc. 2020;383:2427\u201338. https:\/\/doi.org\/10.1056\/NEJMoa2028436.","journal-title":"New Engl J Med Mass Med Soc"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi N","year":"2017","unstructured":"Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nat Nat Publishing Group. 2017;543:248\u201351. https:\/\/doi.org\/10.1038\/nature21428.","journal-title":"Nat Nat Publishing Group"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"eaav5701","DOI":"10.1126\/scitranslmed.aav5701","article-title":"Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice","volume":"12","author":"Willis E","year":"2020","unstructured":"Willis E, Pardi N, Parkhouse K, Mui BL, Tam YK, Weissman D, et al. Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice. Sci Transl Med Am Association Advancement Sci. 2020;12:eaav5701. https:\/\/doi.org\/10.1126\/scitranslmed.aav5701.","journal-title":"Sci Transl Med Am Association Advancement Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/J.YMTHE.2017.12.024","article-title":"Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency","volume":"26","author":"Prieve MG","year":"2018","unstructured":"Prieve MG, Harvie P, Monahan SD, Roy D, Li AG, Blevins TL, et al. Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency. Mol Therapy Cell Press. 2018;26:801\u201313. https:\/\/doi.org\/10.1016\/J.YMTHE.2017.12.024.","journal-title":"Mol Therapy Cell Press"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"7052","DOI":"10.1038\/s41598-020-64017-0","article-title":"Systemic modified messenger RNA for replacement therapy in alpha 1-antitrypsin deficiency","volume":"10","author":"Karadagi A","year":"2020","unstructured":"Karadagi A, Cavedon AG, Zemack H, Nowak G, Eybye ME, Zhu X, et al. Systemic modified messenger RNA for replacement therapy in alpha 1-antitrypsin deficiency. Sci Rep Nat Publishing Group. 2020;10:7052. https:\/\/doi.org\/10.1038\/s41598-020-64017-0.","journal-title":"Sci Rep Nat Publishing Group"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1619653114","author":"Ramaswamy S","year":"2017","unstructured":"Ramaswamy S, Tonnu N, Tachikawa K, Limphong P, Vega JB, Karmali PP et al. Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proceedings of the National Academy of Sciences. National Academy of Sciences; 2017;114:E1941\u201350. https:\/\/doi.org\/10.1073\/pnas.1619653114"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"7322","DOI":"10.1038\/s41467-023-42948-2","article-title":"Lung SORT LNPs enable precise homology-directed repair mediated CRISPR\/Cas genome correction in cystic fibrosis models","volume":"14","author":"Wei T","year":"2023","unstructured":"Wei T, Sun Y, Cheng Q, Chatterjee S, Traylor Z, Johnson LT, et al. Lung SORT LNPs enable precise homology-directed repair mediated CRISPR\/Cas genome correction in cystic fibrosis models. Nat Commun Nat Publishing Group. 2023;14:7322. https:\/\/doi.org\/10.1038\/s41467-023-42948-2.","journal-title":"Nat Commun Nat Publishing Group"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"13594","DOI":"10.1021\/acsnano.3c02268","article-title":"Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease","volume":"17","author":"Palanki R","year":"2023","unstructured":"Palanki R, Bose SK, Dave A, White BM, Berkowitz C, Luks V, et al. Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease. ACS Nano Am Chem Soc. 2023;17:13594\u2013610. https:\/\/doi.org\/10.1021\/acsnano.3c02268.","journal-title":"ACS Nano Am Chem Soc"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering","volume":"20","author":"Billingsley MM","year":"2020","unstructured":"Billingsley MM, Singh N, Ravikumar P, Zhang R, June CH, Mitchell MJ. Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering. Nano Lett. 2020;20:1578\u201389. https:\/\/doi.org\/10.1021\/acs.nanolett.9b04246.","journal-title":"Nano Lett"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","article-title":"Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy","volume":"17","author":"Oberli MA","year":"2017","unstructured":"Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, et al. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017;17:1326\u201335. https:\/\/doi.org\/10.1021\/acs.nanolett.6b03329.","journal-title":"Nano Lett"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/J.JCONREL.2022.03.021","article-title":"Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy","volume":"345","author":"Liu JQ","year":"2022","unstructured":"Liu JQ, Zhang C, Zhang X, Yan J, Zeng C, Talebian F, et al. Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy. J Controlled Release Elsevier. 2022;345:306\u201313. https:\/\/doi.org\/10.1016\/J.JCONREL.2022.03.021.","journal-title":"J Controlled Release Elsevier"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s44222-026-00401-1","article-title":"Design principles of lipid nanoparticles for RNA delivery","author":"Arral ML","year":"2026","unstructured":"Arral ML, Whitehead KA. Design principles of lipid nanoparticles for RNA delivery. Nat Reviews Bioeng Nat Publishing Group. 2026;1\u201318. https:\/\/doi.org\/10.1038\/s44222-026-00401-1.","journal-title":"Nat Reviews Bioeng Nat Publishing Group"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.addr.2016.01.022","article-title":"The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery","volume":"99","author":"Cheng X","year":"2016","unstructured":"Cheng X, Lee RJ. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Deliv Rev Elsevier. 2016;99:129\u201337. https:\/\/doi.org\/10.1016\/j.addr.2016.01.022.","journal-title":"Adv Drug Deliv Rev Elsevier"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/J.JCONREL.2021.05.021","article-title":"Impact of lipid nanoparticle size on mRNA vaccine immunogenicity","volume":"335","author":"Hassett KJ","year":"2021","unstructured":"Hassett KJ, Higgins J, Woods A, Levy B, Xia Y, Hsiao CJ, et al. Impact of lipid nanoparticle size on mRNA vaccine immunogenicity. J Controlled Release Elsevier. 2021;335:237\u201346. https:\/\/doi.org\/10.1016\/J.JCONREL.2021.05.021.","journal-title":"J Controlled Release Elsevier"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/pharmaceutics15020597","article-title":"Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method","volume":"15","author":"Berger M","year":"2023","unstructured":"Berger M, Degey M, Leblond Chain J, Maquoi E, Evrard B, Lechanteur A, et al. Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method. Pharm Multidisciplinary Digit Publishing Inst. 2023;15:597. https:\/\/doi.org\/10.3390\/pharmaceutics15020597.","journal-title":"Pharm Multidisciplinary Digit Publishing Inst"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1038\/mtna.2014.61","article-title":"Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy. Mol. Ther. Nucleic Acids","volume":"3","author":"Kumar V","year":"2014","unstructured":"Kumar V, Qin J, Jiang Y, Duncan RG, Brigham B, Fishman S, et al. Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy. Mol. Ther. Nucleic Acids. Mol Ther Nucleic Acids. 2014;3:e210. https:\/\/doi.org\/10.1038\/mtna.2014.61.","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"119792","DOI":"10.1016\/J.IJPHARM.2020.119792","article-title":"PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM production","volume":"588","author":"Suzuki T","year":"2020","unstructured":"Suzuki T, Suzuki Y, Hihara T, Kubara K, Kondo K, Hyodo K, et al. PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM production. Int J Pharm Elsevier. 2020;588:119792. https:\/\/doi.org\/10.1016\/J.IJPHARM.2020.119792.","journal-title":"Int J Pharm Elsevier"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1021\/acs.nanolett.8b01101","article-title":"Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA","volume":"18","author":"Ball RL","year":"2018","unstructured":"Ball RL, Hajj KA, Vizelman J, Bajaj P, Whitehead KA. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA. Nano Lett Am Chem Soc. 2018;18:3814\u201322. https:\/\/doi.org\/10.1021\/acs.nanolett.8b01101.","journal-title":"Nano Lett Am Chem Soc"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/J.JCONREL.2021.11.022","article-title":"Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery","volume":"341","author":"Melamed JR","year":"2022","unstructured":"Melamed JR, Hajj KA, Chaudhary N, Strelkova D, Arral ML, Pardi N, et al. Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery. J Controlled Release Elsevier. 2022;341:206\u201314. https:\/\/doi.org\/10.1016\/J.JCONREL.2021.11.022.","journal-title":"J Controlled Release Elsevier"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1811276115","author":"Sago CD","year":"2018","unstructured":"Sago CD, Lokugamage MP, Paunovska K, Vanover DA, Monaco CM, Shah NN et al. High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing. Proceedings of the National Academy of Sciences. National Academy of Sciences; 2018;115:E9944\u201352. https:\/\/doi.org\/10.1073\/pnas.1811276115"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nbt.3471","article-title":"Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo","volume":"34","author":"Yin H","year":"2016","unstructured":"Yin H, Song C-Q, Dorkin JR, Zhu LJ, Li Y, Wu Q, et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol NIH Public Access. 2016;34:328\u201333. https:\/\/doi.org\/10.1038\/nbt.3471.","journal-title":"Nat Biotechnol NIH Public Access"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jconrel.2021.10.031","article-title":"Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery","volume":"341","author":"Swingle KL","year":"2022","unstructured":"Swingle KL, Billingsley MM, Bose SK, White B, Palanki R, Dave A, et al. Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery. J Controlled Release. 2022;341:616\u201333. https:\/\/doi.org\/10.1016\/j.jconrel.2021.10.031.","journal-title":"J Controlled Release"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"17056","DOI":"10.1038\/natrevmats.2017.56","article-title":"Tools for translation: non-viral materials for therapeutic mRNA delivery","volume":"2","author":"Hajj KA","year":"2017","unstructured":"Hajj KA, Whitehead KA. Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat Rev Mater Nat Publishing Group. 2017;2:17056. https:\/\/doi.org\/10.1038\/natrevmats.2017.56.","journal-title":"Nat Rev Mater Nat Publishing Group"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.4049\/immunohorizons.1900029","article-title":"Accelerated Blood Clearance of Lipid Nanoparticles Entails a Biphasic Humoral Response of B-1 Followed by B-2 Lymphocytes to Distinct Antigenic Moieties","volume":"3","author":"Besin G","year":"2019","unstructured":"Besin G, Milton J, Sabnis S, Howell R, Mihai C, Burke K, et al. Accelerated Blood Clearance of Lipid Nanoparticles Entails a Biphasic Humoral Response of B-1 Followed by B-2 Lymphocytes to Distinct Antigenic Moieties. Immunohorizons Am Association Immunologists. 2019;3:282\u201393. https:\/\/doi.org\/10.4049\/immunohorizons.1900029.","journal-title":"Immunohorizons Am Association Immunologists"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/J.JCONREL.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage","volume":"172","author":"Abu Lila AS","year":"2013","unstructured":"Abu Lila AS, Kiwada H, Ishida T. The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage. J Controlled Release Elsevier. 2013;172:38\u201347. https:\/\/doi.org\/10.1016\/J.JCONREL.2013.07.026.","journal-title":"J Controlled Release Elsevier"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/J.JCONREL.2020.03.022","article-title":"Evasion of the accelerated blood clearance phenomenon by polysarcosine coating of liposomes","volume":"322","author":"Son K","year":"2020","unstructured":"Son K, Ueda M, Taguchi K, Maruyama T, Takeoka S, Ito Y. Evasion of the accelerated blood clearance phenomenon by polysarcosine coating of liposomes. J Controlled Release Elsevier. 2020;322:209\u201316. https:\/\/doi.org\/10.1016\/J.JCONREL.2020.03.022.","journal-title":"J Controlled Release Elsevier"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/S0022-3565(24)35391-1","article-title":"Accelerated Blood Clearance and Altered Biodistribution of Repeated Injections of Sterically Stabilized Liposomes","volume":"292","author":"Dams ETM","year":"2000","unstructured":"Dams ETM, Laverman P, Oyen WJG, Storm G, Scherphof GL, van der Meer JWM, et al. Accelerated Blood Clearance and Altered Biodistribution of Repeated Injections of Sterically Stabilized Liposomes. J Pharmacol Exp Ther. 2000;292:1071\u20139. https:\/\/doi.org\/10.1016\/S0022-3565(24)35391-1.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1038\/s41551-024-01256-w","article-title":"Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d. Nat","volume":"8","author":"Chaudhary N","year":"2024","unstructured":"Chaudhary N, Kasiewicz LN, Newby AN, Arral ML, Yerneni SS, Melamed JR, et al. Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d. Nat. Biomed Eng Nat Publishing Group. 2024;8:1483\u201398. https:\/\/doi.org\/10.1038\/s41551-024-01256-w.","journal-title":"Biomed Eng Nat Publishing Group"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1038\/s41563-025-02383-8","article-title":"Designing around immune memory to counter PEG immunogenicity","volume":"24","author":"Chaudhary N","year":"2025","unstructured":"Chaudhary N, Whitehead KA. Designing around immune memory to counter PEG immunogenicity. Nat Mater Nat Publishing Group. 2025;24:1666\u20139. https:\/\/doi.org\/10.1038\/s41563-025-02383-8.","journal-title":"Nat Mater Nat Publishing Group"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0813411106","author":"Cole LE","year":"2009","unstructured":"Cole LE, Yang Y, Elkins KL, Fernandez ET, Qureshi N, Shlomchik MJ et al. Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge. Proceedings of the National Academy of Sciences. National Academy of Sciences; 2009;106:4343\u20138. https:\/\/doi.org\/10.1073\/pnas.0813411106"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1038\/s41467-020-16248-y","article-title":"Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver","volume":"11","author":"Miao L","year":"2020","unstructured":"Miao L, Lin J, Huang Y, Li L, Delcassian D, Ge Y, et al. Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver. Nat Commun Springer US. 2020;11:2424. https:\/\/doi.org\/10.1038\/s41467-020-16248-y.","journal-title":"Nat Commun Springer US"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2109256118","author":"Dilliard SA","year":"2021","unstructured":"Dilliard SA, Cheng Q, Siegwart DJ. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proceedings of the National Academy of Sciences. National Academy of Sciences; 2021;118:e2109256118. https:\/\/doi.org\/10.1073\/pnas.2109256118"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1182\/blood.V81.3.617.617","article-title":"In vivo and in vitro regulation of erythropoietin mRNA: measurement by competitive polymerase chain reaction","volume":"81","author":"Fandrey J","year":"1993","unstructured":"Fandrey J, Bunn H. In vivo and in vitro regulation of erythropoietin mRNA: measurement by competitive polymerase chain reaction. Blood Am Soc Hematol. 1993;81:617\u201323. https:\/\/doi.org\/10.1182\/blood.V81.3.617.617.","journal-title":"Blood Am Soc Hematol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12865-021-00448-2","article-title":"Association between serum markers of the humoral immune system and inflammation in the Swedish AMORIS study","volume":"22","author":"Santaolalla A","year":"2021","unstructured":"Santaolalla A, Sollie S, Rislan A, Josephs DH, Hammar N, Walldius G, et al. Association between serum markers of the humoral immune system and inflammation in the Swedish AMORIS study. BMC Immunol BioMed Cent Ltd. 2021;22:61. https:\/\/doi.org\/10.1186\/s12865-021-00448-2.","journal-title":"BMC Immunol BioMed Cent Ltd"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"5370","DOI":"10.4049\/jimmunol.1401849","article-title":"IgH Chain Class Switch Recombination: Mechanism and Regulation","volume":"193","author":"Stavnezer J","year":"2014","unstructured":"Stavnezer J, Schrader CE. IgH Chain Class Switch Recombination: Mechanism and Regulation. J Immunol NIH Public Access. 2014;193:5370\u20138. https:\/\/doi.org\/10.4049\/jimmunol.1401849.","journal-title":"J Immunol NIH Public Access"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.0c00596","author":"Hajj KA","year":"2020","unstructured":"Hajj KA, Melamed JR, Chaudhary N, Lamson NG, Ball RL, Yerneni SS et al. A Potent Branched-Tail Lipid Nanoparticle Enables Multiplexed mRNA Delivery and Gene Editing In Vivo. Nano Lett. American Chemical Society; 2020;20:5167\u201375. https:\/\/doi.org\/10.1021\/acs.nanolett.0c00596"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"eade1444","DOI":"10.1126\/sciadv.ade1444","article-title":"Ionizable lipid nanoparticles deliver mRNA to pancreatic \u03b2 cells via macrophage-mediated gene transfer","volume":"9","author":"Melamed JR","year":"2023","unstructured":"Melamed JR, Yerneni SS, Arral ML, LoPresti ST, Chaudhary N, Sehrawat A, et al. Ionizable lipid nanoparticles deliver mRNA to pancreatic \u03b2 cells via macrophage-mediated gene transfer. Sci Adv Sci Adv. 2023;9:eade1444. https:\/\/doi.org\/10.1126\/sciadv.ade1444.","journal-title":"Sci Adv Sci Adv"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of Lipid Nanoparticles for RNA Delivery","volume":"55","author":"Eygeris Y","year":"2022","unstructured":"Eygeris Y, Gupta M, Kim J, Sahay G. Chemistry of Lipid Nanoparticles for RNA Delivery. Acc Chem Res Am Chem Soc. 2022;55:2\u201312. https:\/\/doi.org\/10.1021\/acs.accounts.1c00544.","journal-title":"Acc Chem Res Am Chem Soc"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"120586","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability","volume":"601","author":"Schoenmaker L","year":"2021","unstructured":"Schoenmaker L, Witzigmann D, Kulkarni JA, Verbeke R, Kersten G, Jiskoot W, et al. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int J Pharm Elsevier. 2021;601:120586. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120586.","journal-title":"Int J Pharm Elsevier"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.JCONREL.2023.02.021","article-title":"Polysarcosine-based lipid formulations for intracranial delivery of mRNA","volume":"356","author":"Bi D","year":"2023","unstructured":"Bi D, Unthan DM, Hu L, Bussmann J, Remaut K, Barz M, et al. Polysarcosine-based lipid formulations for intracranial delivery of mRNA. J Controlled Release Elsevier. 2023;356:1\u201313. https:\/\/doi.org\/10.1016\/J.JCONREL.2023.02.021.","journal-title":"J Controlled Release Elsevier"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/J.BIOACTMAT.2024.03.017","article-title":"Engineering LNPs with polysarcosine lipids for mRNA delivery","volume":"37","author":"Kang DD","year":"2024","unstructured":"Kang DD, Hou X, Wang L, Xue Y, Li H, Zhong Y, et al. Engineering LNPs with polysarcosine lipids for mRNA delivery. Bioact Mater Elsevier. 2024;37:86\u201393. https:\/\/doi.org\/10.1016\/J.BIOACTMAT.2024.03.017.","journal-title":"Bioact Mater Elsevier"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41563-024-02116-3;SUBJMETA","article-title":"High-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics","author":"Xiao Y","year":"2025","unstructured":"Xiao Y, Lian X, Sun Y, Sung YC, Vaidya A, Chen Z, et al. High-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics. Nat Mater Nat Res. 2025;1\u201312. https:\/\/doi.org\/10.1038\/S41563-024-02116-3;SUBJMETA.","journal-title":"Nat Mater Nat Res"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1038\/s41467-022-33157-4","article-title":"Payload distribution and capacity of mRNA lipid nanoparticles","volume":"13","author":"Li S","year":"2022","unstructured":"Li S, Hu Y, Li A, Lin J, Hsieh K, Schneiderman Z, et al. Payload distribution and capacity of mRNA lipid nanoparticles. Nat Commun Nat Publishing Group. 2022;13:5561. https:\/\/doi.org\/10.1038\/s41467-022-33157-4.","journal-title":"Nat Commun Nat Publishing Group"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41582-018-0065-0","article-title":"FDA approves patisiran to treat hereditary transthyretin amyloidosis","volume":"14","author":"Wood H","year":"2018","unstructured":"Wood H. FDA approves patisiran to treat hereditary transthyretin amyloidosis. Nat Rev Neurol Nat Publishing Group. 2018;14:570\u2013570. https:\/\/doi.org\/10.1038\/s41582-018-0065-0.","journal-title":"Nat Rev Neurol Nat Publishing Group"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams D","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang C-C, Ueda M, Kristen AV, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. New Engl J Med Mass Med Soc. 2018;379:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1716153.","journal-title":"New Engl J Med Mass Med Soc"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","article-title":"Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents","volume":"9","author":"Garay RP","year":"2012","unstructured":"Garay RP, El-Gewely R, Armstrong JK, Garratty G, Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv Taylor Francis. 2012;9:1319\u201323. https:\/\/doi.org\/10.1517\/17425247.2012.720969.","journal-title":"Expert Opin Drug Deliv Taylor Francis"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/J.JCONREL.2022.09.031","article-title":"Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products","volume":"351","author":"Ibrahim M","year":"2022","unstructured":"Ibrahim M, Ramadan E, Elsadek NE, Emam SE, Shimizu T, Ando H, et al. Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products. J Controlled Release Elsevier. 2022;351:215\u201330. https:\/\/doi.org\/10.1016\/J.JCONREL.2022.09.031.","journal-title":"J Controlled Release Elsevier"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","article-title":"Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine","volume":"16","author":"Ju Y","year":"2022","unstructured":"Ju Y, Lee WS, Pilkington EH, Kelly HG, Li S, Selva KJ, et al. Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine. ACS Nano Am Chem Soc. 2022;16:11769\u201380. https:\/\/doi.org\/10.1021\/acsnano.2c04543.","journal-title":"ACS Nano Am Chem Soc"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13223-022-00698-8","article-title":"COVID-19 vaccination in a patient with a history of severe polyethylene glycol anaphylaxis. Allergy, Asthma and Clinical Immunology","volume":"18","author":"Li DH","year":"2022","unstructured":"Li DH, Lee E, Song C, Successful mRNA. COVID-19 vaccination in a patient with a history of severe polyethylene glycol anaphylaxis. Allergy, Asthma and Clinical Immunology. BioMed Cent Ltd. 2022;18:1\u20133. https:\/\/doi.org\/10.1186\/S13223-022-00698-8.","journal-title":"BioMed Cent Ltd"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jaip.2021.11.021","article-title":"Safety of COVID-19 vaccination in patients with polyethylene glycol allergy: A case series","volume":"10","author":"Picard M","year":"2022","unstructured":"Picard M, Drolet J-P, Masse M-S, Filion CA, ALMuhizi F, Fein M, et al. Safety of COVID-19 vaccination in patients with polyethylene glycol allergy: A case series. J Allergy Clin Immunol Pract Elsevier. 2022;10:620\u2013e6251. https:\/\/doi.org\/10.1016\/j.jaip.2021.11.021.","journal-title":"J Allergy Clin Immunol Pract Elsevier"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201805097","author":"Hajj KA","year":"2019","unstructured":"Hajj KA, Ball RL, Deluty SB, Singh SR, Strelkova D, Knapp CM et al. Branched-Tail Lipid Nanoparticles Potently Deliver mRNA In Vivo due to Enhanced Ionization at Endosomal pH. Small. Wiley-VCH Verlag; 2019;15:1805097. https:\/\/doi.org\/10.1002\/smll.201805097"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1038\/ncomms5277","article-title":"Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity","volume":"5","author":"Whitehead KA","year":"2014","unstructured":"Whitehead KA, Dorkin JR, Vegas AJ, Chang PH, Veiseh O, Matthews J, et al. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat Commun Nat Publishing Group. 2014;5:4277. https:\/\/doi.org\/10.1038\/ncomms5277.","journal-title":"Nat Commun Nat Publishing Group"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9763025\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9763025\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:18:48Z","timestamp":1792426728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9763025\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":54,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9763025\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1007\/s13346-026-02225-3","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2026,6,9]]},"subtype":"preprint"}}